Henry Schein Sees FY21 EPS Below Consensus, But Q2 Earnings Beat Expectations

  • Henry Schein Inc HSIC posts Q2 net sales of $2.97 billion, beating the consensus of $2.89 billion, up 76.2% Y/Y when a significant number of dental and medical practices suspended activity due to the COVID-19 pandemic. 
  • Compared with the pre-pandemic Q2 of 2019, sales were up 21.2% and included 15.2% internal growth in local currencies, 4.2% growth from acquisitions, and 1.8% growth related to foreign currency exchange.
  • Global Dental sales doubled to $1.9 billion, and Medical sales of $904.8 million increased 46.5%.
  • The gross margin expanded from 27% to 30%, and the operating income was $210.3 million, a turnaround from a loss of $(7.4) million posted a year ago.
  • Adjusted EPS of $1.11 beat estimate of $0.97.
  • FY21 Guidance: Henry Schein expects an adjusted EPS of over $3.85, up from previous guidance of $3.70+, but lower than the consensus of $4.14.
  • Price Action: HSIC shares are down 1.99% at $79.61 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceShort IdeasHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!